Abstract
[186gRe]Re-HEDP is a radiopharmaceutical used for pain palliation in bone metastases from various primary tumors. The negatron emitter with 〈Eβ〉 = 357 keV 186gRe is suitable to irradiate cancer and inflammatory cells, but it needs labeling bis-phosphonates as vectors to reach target tissue. Paper radiochromatography was used to evaluate the radiochemical purity of [186gRe]Re-HEDP in radiopharmaceutical solution as well as in biological samples (serum and urine) from treated patients, in order to follow bone-targeting and excretion. Following the activity concentration in each sample vs. time it is effective to elaborate a bio-kinetic model of the radiopharmaceutical and to optimize administration protocols.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
